共 168 条
[1]
Takechi T(1997)Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats Cancer Chemother Pharmacol 39 205-11
[2]
Nakano K(1998)Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous infusion of 5-fluorouracil Anticancer Drugs 9 817-23
[3]
Uchida J(1998)Preclinical antitumor efficacy of S-1 2-a: a new oral formulation of 5-fluorouracil on human tumor xenografts Int J Oncol 13 693-8
[4]
Mita A(1993)Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004-9
[5]
Toko K(1981)Metabolism of 5-fluorouracil in various human normal and tumor tissues Gann 72 824-7
[6]
Takeda S(1995)Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity J Clin Oncol 13 1663-70
[7]
Fukushima M(1987)Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res (Gann) 78 748-55
[8]
Shimamoto Y(1999)An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers Oncology 57 202-10
[9]
Kato T(1998)Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur–0.4 M gimestat–1 M otastat pottassium) in advanced gastric cancer patients Eur J Cancer 34 1715-20
[10]
Uchida J(2000)Hasegawa K, and the S-1 gastrointestinal cancer study group. Phase II study for S-1, a novel derivative of 5-fluorouracil, in advanced gastric cancer Oncology 58 191-7